Use of antidepressants and the risk of Parkinson's disease: A prospective study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 80, Issue 6, 2009, Pages 671-674

  Alonso, A ^a   Garcia Rodriguez L A ^b   Logroscino, G ^c   Hernan M A ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Department of Pharmacoepidemiology   (Spain)

^c UNIVERSITY OF BARI   (Italy)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; FLUOXETINE; IMIPRAMINE; LOFEPRAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG MEGADOSE; DRUG USE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION; COMORBIDITY; DOSE RESPONSE; EARLY DIAGNOSIS; FOLLOW UP; RISK; UNITED KINGDOM;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COMORBIDITY; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY DIAGNOSIS; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; ODDS RATIO; PARKINSON DISEASE; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS;

EID: 66149134862     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.152983     Document Type: Article

References (22)

1. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-1793 (Pubitemid 38698383)
2. Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007;69:342-347 (Pubitemid 47205660)
3. Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson's disease for patients with major affective disorders: a register study. Acta Psychiatr Scand 2001;104:380-386 (Pubitemid 34280555)
4. Schuurman AG, van den Akker M, Ensinck KT JL, et al. Increased risk of Parkinson's disease after depression: A retrospective cohort study. Neurology 2002;58:1501-1504 (Pubitemid 34552956)
5. Brandt-Christensen M, Kvist K, Nilsson FM, et al. Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: a pharmacoepidemiological study. J Neurol Neurosurg Psychiatry 2006;77:781-783 (Pubitemid 43837208)
6. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 2006;113:211-220 (Pubitemid 43382593)
7. Mayeux R. Depression in the patient with Parkinson's disease. J Clin Psychiatry 1990;51(Suppl):20-23 (Pubitemid 20231054)
8. Mallet L, Schupbach M, N'Diaye K, et al. Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci U S A 2007;104:10661-10666 (Pubitemid 47185721)
9. Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006;59:1151-1159 (Pubitemid 44192421)
10. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-768
11. Jick H, Terris BZ, Derby LE, et al. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992;1:347-349
12. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the General Practice Research Database. Pharmacotherapy 2003;23:686-689 (Pubitemid 36539051)
13. Hernán MA, Logroscino G, García-Rodríguez LA. A prospective study of alcoholism and the risk of Parkinson's disease. J Neurol 2004;251:vii14-vii7.
14. Hernán MA, Logroscino G, García-Rodríguez LA. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson's disease. Neurology 2006;66:1097-1099
15. Hernán MA, Robins JM, García-Rodríguez LA. Statistical issues arising in the Women's Health Initiative - Discussion. Biometrics 2005;61:922-930
16. Alonso A, Garcia-Rodriguez LA, Logroscino G, et al. Gout and risk of Parkinson disease: A prospective study. Neurology 2007;69:1696-1700 (Pubitemid 350287126)
17. Leentjens AF, Van den Akker M, Metsemakers JF, et al. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003;18:414-418 (Pubitemid 36527282)
18. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000;15:669-677 (Pubitemid 30479619)
19. Ghazi-Noori S, Chung TH, Deane KHO, et al. Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev 2003:CD003465.
20. Mitchell AJ. High medication discontinuation rates in psychiatry. How often is it understandable? J Clin Psychopharmacol 2006;26:109-112
21. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007;64:327-337 (Pubitemid 46376789)
22. Thacker EL, Chen H, Patel AV, et al. Recreational physical activity and risk of Parkinson's disease. Mov Disord 2008;23:69-74. (Pubitemid 351281220)